EP2975021B1 - Process for the preparation of iopamidol - Google Patents

Process for the preparation of iopamidol Download PDF

Info

Publication number
EP2975021B1
EP2975021B1 EP15179960.8A EP15179960A EP2975021B1 EP 2975021 B1 EP2975021 B1 EP 2975021B1 EP 15179960 A EP15179960 A EP 15179960A EP 2975021 B1 EP2975021 B1 EP 2975021B1
Authority
EP
European Patent Office
Prior art keywords
formula
compound
group
straight
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP15179960.8A
Other languages
German (de)
French (fr)
Other versions
EP2975021A1 (en
Inventor
Pier Lucio Anelli
Marino Brocchetta
Giovanna Lux
Enrico Cappelletti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco Imaging SpA
Original Assignee
Bracco Imaging SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Imaging SpA filed Critical Bracco Imaging SpA
Publication of EP2975021A1 publication Critical patent/EP2975021A1/en
Application granted granted Critical
Publication of EP2975021B1 publication Critical patent/EP2975021B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00Preparation of carboxylic acid amides
    • C07C231/02Preparation of carboxylic acid amides from carboxylic acids or from esters, anhydrides, or halides thereof by reaction with ammonia or amines

Definitions

  • the present invention relates to a new process for the preparation of iopamidol (i.e. (S) - N , N '-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl) amino]-2,4,6-triiodo-1, 3-benzenedicarboxamide) starting from the corresponding 5-unsubstitued amino derivative.
  • iopamidol i.e. (S) - N , N '-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl) amino]-2,4,6-triiodo-1, 3-benzenedicarboxamide
  • WO 00/50385 has recently described a process for the preparation of polyhydroxy compounds (including i.e. iopamidol) comprising the step of deacylating, under acidic conditions, an acylated compound having the formula: wherein R 4 and R 5 are optionally acylated dihydroxyalkyl groups, R 6 is alkyl and R 3 is i.a. a methyl group.
  • the acid used in this deacylation reaction is then removed by batch treatment with an acid scavenging resin; an aqueous solution of the thus obtained product is purified by passing through a non-ionic polymeric adsorbent resin; the eluate is concentrated to an oil; and the oil is crystallised from acetonitrile/ethanol or ethanol.
  • the above method is said to reduce racemization at the chiral carbon that - according to WO 00/50385 - occurs whenever basic conditions are employed to remove the R 6 CO-protecting group of the chiral substituent.
  • acyl groups reported in WO 00/50385 are formyl, acetyl, propanoyl, butanoyl, pivaloyl, pentanoyl, trifluoroacetyl, and benzoyl.
  • WO 00/50385 describes the preparation of the starting acylated compound through introduction of the R 6 CO -protected chiral substituent on the 5-amino group of a tetraester of the 5-amino-2,4,6-triiodo-1,3-benzenedicarboxamide.
  • the isolated pentacylated product is then converted into iopamidol by the claimed process that requires deacylation under drastic acidic conditions. More particularly the actual conditions exemplified in WO 00/50385 for iopamidol are heating the pentacetyl derivative at the reflux temperature with hydrochloric acid in methanol for 30 hours.
  • a first object of the present invention is therefore a process for the preparation of iopamidol (I) starting from the compound of formula (II) which process comprises
  • the compound of formula (II) is a known product and its preparation can be carried out by any of the known methods, such as those described in GB 1472050 , CH 627653 or US 5, 278, 311 .
  • step a) of the process of the present invention the compound (II) is reacted with a compound which is suitably selected among aldehydes, ketones (possibly in the corresponding acetal or ketal related forms), orthoesters, or anhydrides, depending on the type of protecting group to be introduced.
  • the compound (II) will be reacted with a di-(C 1 -C 4 )alkoxy-methane when both R 1 , and R 2 are hydrogen, with the suitably selected aldehydes or ketones of formula R 1 COR 2 (possibly in the corresponding acetal or ketal related forms) in the presence of a small amount of a tri-(C 1 -C 4 )alkyl orthoformate as dehydrating agent when R 1 is a hydrogen atom or a C 1 ⁇ C 4 straight or branched alkyl group and R 2 is a C 1 -C 4 straight or branched alkyl group or with orthoesters of formula R 1 C (R 2 ) 3 when at least R 2 is an alkoxy group.
  • -R in the compounds (III) represents a group of formula A
  • preferred compounds are those wherein both R 1 and R 2 are C 1 ⁇ C 4 straight or branched alkyl groups; more preferred are those wherein both R 1 and R 2 are C1 ⁇ C 4 straight alkyl groups; and even more preferred are those wherein both R 1 and R 2 are methyl.
  • Another group of preferred compounds (III) wherein -R represents a group A are those wherein R 1 is hydrogen and R 2 is a C 1 ⁇ C 4 straight alkoxy group.
  • step a) is carried out in the presence of an organic solvent selected from the dipolar organic solvents, e. g. N, N- dimethylformamide, N , N- dimethylacetamide, and N -methyl-2-pyrrolidone, the inert aprotic organic solvents, and the mixtures thereof.
  • an organic solvent selected from the dipolar organic solvents, e. g. N, N- dimethylformamide, N , N- dimethylacetamide, and N -methyl-2-pyrrolidone, the inert aprotic organic solvents, and the mixtures thereof.
  • the reaction is carried out using at least the stoichiometric amount of the reactants but preferably at least a slight excess of the reactant introducing the protecting group with respect to the starting compound (II).
  • the reaction is typically carried out at room temperature but lower or higher temperatures may as well be employed. As an example, temperatures in the range of from about 5°C to about 60°C proved to be suitable for step a).
  • step a) The introduction of the protecting group in step a) is preferably carried out under slightly different reaction conditions depending on the particular reactant employed. The person skilled in the art will be aware of these differences and will be able to optimise the reaction conditions on the basis of his personal knowledge.
  • step a) in the above process will be preferably carried out in the presence of an acidic catalyst. More particularly the reaction will be preferably carried out in the presence of from about 0.1 to about 2 mol of an acid per mol of compound of formula (II).
  • Suitable acids that can be employed in this step are for instance sulfuric acid, hydrochloric acid, methanesulfonic acid, p-toluenesulfonic acid, or carboxylic acids, such as formic acid, acetic acid, or propionic acid
  • the preferred reactant is acetone in the presence of a small amount of a tri-(C 1 ⁇ C 4 )alkyl orthoformate or 2,2-dimethoxypropane, while for the preparation of the compounds of formula (III) wherein -R is an A group wherein R 1 is hydrogen and R 2 is a C 1 ⁇ C 4 straight alkoxy group, the preferred reactants are the corresponding tri-(C 1 ⁇ C 4 ) straight alkyl orthoformates.
  • the reaction will be preferably carried out by dripping a mixture of an excess over the stoichiometric of the suitably selected ketone/ketal or orthoformate together with a catalytic amount, typically about 0.1 mol per mol of compound of formula (II), of a strong acid, preferably sulfuric or methanesulfonic acid, into a solution of the compound of formula (II) in a dipolar aprotic solvent, typically N , N- dimethylacetamide.
  • a catalytic amount typically about 0.1 mol per mol of compound of formula (II)
  • a strong acid preferably sulfuric or methanesulfonic acid
  • the protected compound of formula (III) wherein -R is a group of formula A is isolated, through neutralisation of the acidic catalyst, precipitation of the desired compound (III) by the addition of a diluted (generally 3 % by weight) solution of bicarbonate, and purification of the precipitate by crystallisation from ethanol and water.
  • Step b) in the overall process outlined above consists in the acylation reaction of the primary amino group of the compounds of formula (III), with at least 1 mol of (S)-2-(acetyloxy) propanoyl chloride to give the compounds of formula (IV).
  • the reaction is usually carried out in an inert dipolar aprotic solvent such as N , N -dimethylacetamide, N , N -dimethylformamide, 1-methyl-2 pyrrolidone and the like solvents and in presence of an acid.
  • dipolar aprotic solvent such as N , N -dimethylacetamide, N , N -dimethylformamide, 1-methyl-2 pyrrolidone and the like solvents and in presence of an acid.
  • Acids that can suitably be employed in step b) are for instance hydrohalic acid that can easily be introduced into the reaction mixture as the hydrohalide salts of the dipolar aprotic solvents employed, such as the N,N-dimethylacetamide hydrochloride or-preferably-by bubbling the anhydrous hydrogen chloride gas into the reaction mixture.
  • the acid is typically employed in an amount of from about 01.1 to about 0.4 mol per mol of product of formula (III);
  • the temperature for this step of the reaction is generally comprised between about 5 and about 60°C.
  • the reaction is carried out at room temperature or a temperature slightly above room temperature (about 45-50°C).
  • step b) is typically complete in a time comprised between about 2 and about 20 hours, depending on the solvent employed and the reaction conditions adopted.
  • step c) all the acyl groups which are present in the intermediate compound of formula (IV) are removed under basic conditions, with prior cleavage of the cyclic protections under acidic conditions when R is a group of formula A.
  • the basic hydrolysis is carried out typically in water or in a mixture of water and an organic solvent miscible therewith such as a C 1 ⁇ C 4 straight or branched alkanol, or a dipolar aprotic organic solvent such as N,N dimethylformamide, N , N -dimethylacetamide, 1-methyl-2-pyrrolidone, and the like solvents.
  • an organic solvent miscible therewith such as a C 1 ⁇ C 4 straight or branched alkanol, or a dipolar aprotic organic solvent such as N,N dimethylformamide, N , N -dimethylacetamide, 1-methyl-2-pyrrolidone, and the like solvents.
  • the pH of the reaction mixture is maintained between 10 and 11 by the addition of a strong inorganic base such as NaOH or KOH, typically as an aqueous solution thereof.
  • a strong inorganic base such as NaOH or KOH
  • the reaction is preferably carried out at room temperature but temperatures of from about 10 °C to about 60 °C proved to be useful.
  • a strong cation exchange resin preferably Duolite C20MB, Amberlite IR120 or Amberjet 1200 (Rohm & Haas) or of an aqueous solution of a strong mineral acid, e. g. hydrochloric or sulfuric acid, to a solution of the compound of formula (IV) wherein -R is a group A, in water or in a mixture of water and an organic solvent miscible therewith such as a C 1 ⁇ C 4 straight or branched alkanol, or a dipolar aprotic organic solvent such as N , N -dimethylformamide, N , N -dimethylacetamide, 1-methyl-2-pyrrolidone, and the like solvents.
  • a strong cation exchange resin preferably Duolite C20MB, Amberlite IR120 or Amberjet 1200 (Rohm & Haas) or of an aqueous solution of a strong mineral acid, e. g. hydrochloric or sulfuric acid, to
  • the amount of acid required in this step is comprised between about 0.2 and about 0.4 mol of acid per mol of compound of formula (IV) wherein -R is a group A.
  • the reaction is preferably carried out at a temperature slightly above room temperature, e. g. comprised between about 40 °C and about 55 °C, and is typically complete in 2 to 5 hours depending on the reaction conditions employed.
  • the isolation of the product of formula (I) from the basic aqueous solution thus obtained is usually carried out by passing the solution on a system of ionic exchange resins and optionally through a nanofiltration unit, as described for example in US-A-5,811,581 or EP-A-888,190 , followed by crystallization of the product (I) from a lower alkanol, as described for instance in US-A-5,571,941 .
  • Preferred among the compounds of formula (III) and (IV) wherein-R is a group A are those wherein R 1 and R 2 are C 1 ⁇ C 4 straight or branched alkyl groups; more preferred are those wherein both R 1 and R 2 are C 1 ⁇ C 4 straight alkyl groups; and even more preferred are those wherein both R 1 and R 2 are methyl.
  • Another group of preferred compounds (III) and (IV) wherein -R represents a group A are those wherein R 1 is hydrogen and R 2 is a C 1 ⁇ C 4 straight alkoxy group.
  • 2,2-Dimethoxypropane (9.5 mL, 77.8 mmol) and 98% sulfuric acid (0.25 g, 2.6 mmol) are dripped into a 0.5 L vessel containing a solution of the compound of formula (II) (18.3 g, 25.9 mmol) (prepared as described in GB1472050 ) in dimethylacetamide (90 mL) stirred at room temperature. After 20 hours under stirring the solution is neutralised with NaHCO 3 and concentrated under vacuum. Acetone (250 mL) and 3 % aq.
  • Methanesulfonic acid (0.27 g, 2.8 mmol) and triethyl orthoformate (9.25 g, 62.4 mmol) are dripped in 1 hour into a solution of the compound of formula (II) (20 g, 28.4 mmol) (prepared as described in GB1472050 ) in N,N- dimethylacetamide (150 mL) stirred at 25 °C. After 1 hour the solution is neutralised with NaHCO 3 The solvent is evaporated under vacuum and the oily residue is taken up with aq. 5 % NaHC0 3 (300 mL).
  • Triethyl orthoformate (18.6 g, 125.5 mmol) is added over 3 min to a solution of the compound of formula (II) (40 g, 57 mmol) and methanesulfonic acid (0.55 g, 5.7 mmol) in N , N -dimethylacetamide (400 mL), stirred at room temperature. After 15 min, the reaction mixture is neutralized with 1M NaOH (5.7 mL, 5.7 mmol) and N , N -dimethylacetamide is distilled to give an oily residue. The latter is poured into 1% aq.
  • Acetic anhydride (9 mL, 95 mmol) is dripped into a suspension of the compound of formula (II) (7 g, 10 mmol) (prepared as described in GB1472050 ) in pyridine (40 mL) stirred at 25 °C. After 3 hours, the solution obtained is added dropwise to deionized water (0.3 L) and the precipitate is recovered by filtration, washed with 5 % acetic acid, then with deionized water, and finally dried under vacuum at the temperature of 40 °C for 12 hour to obtain the compound of the title (7.86 g, 9 mmol). Yield: 90 % The 1 H-NMR, 13 C-NMR, IR and MS are consistent with the indicated structure.
  • N N '-bis[2-acetyloxy-1-[(acetyloxy)methyl]ethyl]-5-amino-2,4,6-triiodo-1,3-benzenedicarboxamide ((III): -R is a group B where R 3 is methyl)
  • the compound of formula (II) (1486 g, 2.1 mol) is loaded into a 10 L reactor containing N,N- dimethylacetamide (1.7 L) and 4-dimethylaminopyridine (12.9 g) is then added thereto.
  • Acetic anhydride (0.9 kg, 8.82 mol) is dripped therein over about 1 hour keeping the temperature below 30 °C.
  • the reaction mixture is stirred at room temperature for 20 hours, and then diluted with 96% ethanol (7.5 L).
  • the precipitate is filtered, washed with 96% ethanol (2 x 1L) and dried to give the compound of the title (1715 g, 1.96 mol). Yield: 94 %
  • the 1 H-NMR, 13 C-NMR, IR and MS are consistent with the indicated structure.
  • the mother liquors, combined with the washings, are concentrated to an oily residue, which is diluted with water (200 mL) and nanofiltered.
  • the retentate is loaded onto an Amberlite ® XAD-16.00 resin column (160 mL) that is eluted with water.
  • the eluate is concentrated and loaded onto two ion exchange resin columns (Dowex ® C350 15 mL, Relite ® MG1 10 mL).
  • the eluate is concentrated and the solid residue is crystallized from ethanol to afford Iopamidol (41.2 g, 53 mmol). Yield: 87%.
  • ⁇ 436 20 ⁇ 5.15 40 % H 2 O .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

  • The present invention relates to a new process for the preparation of iopamidol (i.e. (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl) amino]-2,4,6-triiodo-1, 3-benzenedicarboxamide) starting from the corresponding 5-unsubstitued amino derivative.
  • BACKGROUND OF THE INVENTION
  • (S)-N,N'-bis [2-hydroxy-1-(hydroxymethyl) ethyl]-5-[(2-hydroxy-1-oxopropyl) amino]-2,4,6-triiodo-1,3-benzenedicarboxamide of formula (I).
    Figure imgb0001
    which is known as Iopamidol, is one of the most widely employed non-ionic radiographic contrast agents in the world.
  • It was first described in GB1472050 , where its synthesis by the process outlined in the following Scheme has been reported:
    Figure imgb0002
  • The above process, that is still widely employed industrially, has anyway several drawbacks.
  • One of them is the introduction of the protected chiral synton (S)-2-(acetyloxy)propanoyl on the 5-amino group at an early stage of the overall process, i. e. before the amidation with 2-amino-1,3-propanediol.
  • Just introducing this chiral group via reaction of the 5-amino-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-1,3-benzenedicarboxamide with (S)-2-(acetyloxy)propanoyl chloride would lead to the preferential acylation of the more reactive hydroxy groups of the carboxamido substituents, thus causing remarkable wasting of expensive reactant.
  • WO 00/50385 has recently described a process for the preparation of polyhydroxy compounds (including i.e. iopamidol) comprising the step of deacylating, under acidic conditions, an acylated compound having the formula:
    Figure imgb0003
    wherein R4 and R5 are optionally acylated dihydroxyalkyl groups, R6 is alkyl and R3 is i.a. a methyl group.
  • According to WO 00/50385 the acid used in this deacylation reaction is then removed by batch treatment with an acid scavenging resin; an aqueous solution of the thus obtained product is purified by passing through a non-ionic polymeric adsorbent resin; the eluate is concentrated to an oil; and the oil is crystallised from acetonitrile/ethanol or ethanol.
  • The above method is said to reduce racemization at the chiral carbon that - according to WO 00/50385 - occurs whenever basic conditions are employed to remove the R6CO-protecting group of the chiral substituent.
  • Examples of acyl groups reported in WO 00/50385 are formyl, acetyl, propanoyl, butanoyl, pivaloyl, pentanoyl, trifluoroacetyl, and benzoyl.
  • For iopamidol, WO 00/50385 describes the preparation of the starting acylated compound through introduction of the R6CO -protected chiral substituent on the 5-amino group of a tetraester of the 5-amino-2,4,6-triiodo-1,3-benzenedicarboxamide. The isolated pentacylated product is then converted into iopamidol by the claimed process that requires deacylation under drastic acidic conditions. More particularly the actual conditions exemplified in WO 00/50385 for iopamidol are heating the pentacetyl derivative at the reflux temperature with hydrochloric acid in methanol for 30 hours.
  • SUMMARY OF THE INVENTION
  • It has now been found, and represents a first object of the present invention, that it is possible to carry out the deacylation of a pentacylated iopamidol, under basic conditions getting a final product, iopamidol, that has an extremely high optical purity.
  • Furthermore, it has been found that according to the process of the present invention it is not necessary to isolate the pentacylated product;
    more particularly, it has been found that introducing the (S)-2-(acetyloxy)propanoyl substituent onto the 5-amino group of a N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-1,3-benzenedicarboxamide wherein the hydroxy groups of the carboxamido substituents have been suitably acylated and then removing all the acyl groups under basic conditions without isolating the intermediate product, the overall process does proceed with very high yield.
  • Finally, it has been found that the process according to the present invention can be employed, with some modification, also when protection of the hydroxy groups of the carboxamido substituents is achieved by conversion of these groups into optionally 2-monosubstituted or 2,2-disubstituted N,N'-bis (1,3-dioxan-5-yl)carboxamides.
  • The intermediates5-amino-N,N'-bis(optionally 2-monosubstituted or 2,2-disubstituted-1,3-dioxan-2-yl)-2,4,6-triiodo-1,3-benzenecarbox- amides (III) as well as the (S)-N,N'-bis(optionally 2-monosubstituted or 2,2-disubstituted-1,3-dioxan-2-yl)-5- [2-acetoxy-1-(oxopropyl)amino]-2,4,6-triiodo-1,3-benzenecarboxamides (IV) are also disclosed in the present invention.
  • DETAILED DESCRIPTION OF THE PRESENT INVENTION
  • A first object of the present invention is therefore a process for the preparation of iopamidol (I)
    Figure imgb0004
    starting from the compound of formula (II)
    Figure imgb0005
    which process comprises
    1. a) reacting the compound of formula (II) with a suitable protecting agent, to give a compound of formula (III)
      Figure imgb0006
      wherein -R is a group of formula A
      Figure imgb0007
      wherein R1, is a hydrogen atom, a C1÷C4 straight or branched alkyl group or a C1÷C4 straight or branched alkoxy group, R2 is a hydrogen atom, a C1÷C4 straight or branched alkyl group or a C1÷C4 straight or branched alkoxy group;
    2. b) acylating the amino group in position 5 of the intermediate compound of formula (III), by reaction with a (S)-2- (acetyloxy) propanoyl chloride to give a compound of formula (IV)
      Figure imgb0008
      wherein R is as defined above; and
    3. c) removing all the acyl groups present in the compound of formula (IV) under basic conditions, with prior cleavage of the cyclic protections (of the hydroxy carboxamido substituents) under acidic conditions and wherein intermediate compound (IV) obtained in step b) is further reacted without being isolated.
  • The compound of formula (II) is a known product and its preparation can be carried out by any of the known methods, such as those described in GB 1472050 , CH 627653 or US 5, 278, 311 .
  • According to step a) of the process of the present invention the compound (II) is reacted with a compound which is suitably selected among aldehydes, ketones (possibly in the corresponding acetal or ketal related forms), orthoesters, or anhydrides, depending on the type of protecting group to be introduced.
  • For instance when -R in the compounds (III) represents a group of formula A, the compound (II) will be reacted with a di-(C1-C4)alkoxy-methane when both R1, and R2 are hydrogen, with the suitably selected aldehydes or ketones of formula R1COR2 (possibly in the corresponding acetal or ketal related forms) in the presence of a small amount of a tri-(C1-C4)alkyl orthoformate as dehydrating agent when R1 is a hydrogen atom or a C1÷C4 straight or branched alkyl group and R2 is a C1-C4 straight or branched alkyl group or with orthoesters of formula R1C (R2)3 when at least R2 is an alkoxy group.
  • When -R in the compounds (III) represents a group of formula A, preferred compounds are those wherein both R1and R2 are CC4 straight or branched alkyl groups; more preferred are those wherein both R1 and R2 are C1÷C4 straight alkyl groups; and even more preferred are those wherein both R1 and R2 are methyl.
  • Another group of preferred compounds (III) wherein -R represents a group A are those wherein R1 is hydrogen and R2 is a CC4 straight alkoxy group.
  • The reaction of step a) is carried out in the presence of an organic solvent selected from the dipolar organic solvents, e. g. N, N-dimethylformamide, N,N-dimethylacetamide, and N-methyl-2-pyrrolidone, the inert aprotic organic solvents, and the mixtures thereof.
  • The reaction is carried out using at least the stoichiometric amount of the reactants but preferably at least a slight excess of the reactant introducing the protecting group with respect to the starting compound (II).
  • Needless to say that if a compound of formula (III) is desired wherein - R is a group A, at least two mol of the corresponding aldehyde or ketone (also in the form of the corresponding acetal or ketal) or orthoester have to be employed per mol of starting (II). A slight excess, e. g. at least an excess of about 5 % by mol over the stoichiometric amount is typically employed, a molar excess of up to about 50 % being preferred.
  • The reaction is typically carried out at room temperature but lower or higher temperatures may as well be employed. As an example, temperatures in the range of from about 5°C to about 60°C proved to be suitable for step a).
  • The introduction of the protecting group in step a) is preferably carried out under slightly different reaction conditions depending on the particular reactant employed. The person skilled in the art will be aware of these differences and will be able to optimise the reaction conditions on the basis of his personal knowledge.
  • As an example, when in the compound (III) -R is a group of formula A, then step a) in the above process will be preferably carried out in the presence of an acidic catalyst. More particularly the reaction will be preferably carried out in the presence of from about 0.1 to about 2 mol of an acid per mol of compound of formula (II). Suitable acids that can be employed in this step are for instance sulfuric acid, hydrochloric acid, methanesulfonic acid, p-toluenesulfonic acid, or carboxylic acids, such as formic acid, acetic acid, or propionic acid
  • For the preparation of the most preferred compound of formula (III) wherein -R is an A group wherein R1 and R2 are both methyl groups, the preferred reactant is acetone in the presence of a small amount of a tri-(C1÷C4)alkyl orthoformate or 2,2-dimethoxypropane, while for the preparation of the compounds of formula (III) wherein -R is an A group wherein R1 is hydrogen and R2 is a C1÷C4 straight alkoxy group, the preferred reactants are the corresponding tri-(C1÷C4) straight alkyl orthoformates.
  • In the actual practice, in the above case, the reaction will be preferably carried out by dripping a mixture of an excess over the stoichiometric of the suitably selected ketone/ketal or orthoformate together with a catalytic amount, typically about 0.1 mol per mol of compound of formula (II), of a strong acid, preferably sulfuric or methanesulfonic acid, into a solution of the compound of formula (II) in a dipolar aprotic solvent, typically N,N-dimethylacetamide.
  • Once the reaction, that may take from few minutes to 30 hours to be complete, is over, the protected compound of formula (III) wherein -R is a group of formula A is isolated, through neutralisation of the acidic catalyst, precipitation of the desired compound (III) by the addition of a diluted (generally 3 % by weight) solution of bicarbonate, and purification of the precipitate by crystallisation from ethanol and water.
  • Step b) in the overall process outlined above consists in the acylation reaction of the primary amino group of the compounds of formula (III), with at least 1 mol of (S)-2-(acetyloxy) propanoyl chloride to give the compounds of formula (IV).
  • The reaction is usually carried out in an inert dipolar aprotic solvent such as N,N-dimethylacetamide, N,N-dimethylformamide, 1-methyl-2 pyrrolidone and the like solvents and in presence of an acid.
  • Acids that can suitably be employed in step b) are for instance hydrohalic acid that can easily be introduced into the reaction mixture as the hydrohalide salts of the dipolar aprotic solvents employed, such as the N,N-dimethylacetamide hydrochloride or-preferably-by bubbling the anhydrous hydrogen chloride gas into the reaction mixture.
  • The acid is typically employed in an amount of from about 01.1 to about 0.4 mol per mol of product of formula (III);
  • The temperature for this step of the reaction is generally comprised between about 5 and about 60°C.
  • Preferably, however, the reaction is carried out at room temperature or a temperature slightly above room temperature (about 45-50°C).
  • The reaction of step b) is typically complete in a time comprised between about 2 and about 20 hours, depending on the solvent employed and the reaction conditions adopted.
  • In the following step c) all the acyl groups which are present in the intermediate compound of formula (IV) are removed under basic conditions, with prior cleavage of the cyclic protections under acidic conditions when R is a group of formula A.
  • In particular when a compound (IV) is employed wherein -R is a group of formula A, the basic hydrolysis to remove the acetyl protecting group of the 5-[(2-hydroxy-1-oxopropyl)amino] is preceded by cleavage of the cyclic protections of the carboxamido hydroxy groups under acidic conditions.
  • The basic hydrolysis is carried out typically in water or in a mixture of water and an organic solvent miscible therewith such as a C1÷C4 straight or branched alkanol, or a dipolar aprotic organic solvent such as N,N dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, and the like solvents.
  • The pH of the reaction mixture is maintained between 10 and 11 by the addition of a strong inorganic base such as NaOH or KOH, typically as an aqueous solution thereof. The reaction is preferably carried out at room temperature but temperatures of from about 10 °C to about 60 °C proved to be useful.
  • As indicated above, when in the compound of formula (IV) -R is a group of formula A, the basic hydrolysis of the acetyl group has to be preceded by the cleavage of the cyclic protections of the hydroxy groups of the carboxamido substituents under acidic conditions.
  • This is easily achieved by the addition of a strong cation exchange resin, preferably Duolite C20MB, Amberlite IR120 or Amberjet 1200 (Rohm & Haas) or of an aqueous solution of a strong mineral acid, e. g. hydrochloric or sulfuric acid, to a solution of the compound of formula (IV) wherein -R is a group A, in water or in a mixture of water and an organic solvent miscible therewith such as a C1÷C4 straight or branched alkanol, or a dipolar aprotic organic solvent such as N,N-dimethylformamide, N,N-dimethylacetamide, 1-methyl-2-pyrrolidone, and the like solvents.
  • The amount of acid required in this step is comprised between about 0.2 and about 0.4 mol of acid per mol of compound of formula (IV) wherein -R is a group A. The reaction is preferably carried out at a temperature slightly above room temperature, e. g. comprised between about 40 °C and about 55 °C, and is typically complete in 2 to 5 hours depending on the reaction conditions employed.
  • The hydrolysis under basic conditions to yield the end iopamidol is then just obtained by adding an aqueous solution of NaOH or KOH directly thereto in such an amount to keep the pH between about 10 and about 11.
  • The isolation of the product of formula (I) from the basic aqueous solution thus obtained, is usually carried out by passing the solution on a system of ionic exchange resins and optionally through a nanofiltration unit, as described for example in US-A-5,811,581 or EP-A-888,190 , followed by crystallization of the product (I) from a lower alkanol, as described for instance in US-A-5,571,941 . The intermediate compounds of formula (III) and (IV), wherein-R is a group of formula A
    Figure imgb0009
    Figure imgb0010
    wherein R1 is a hydrogen atom, a C1÷C4 straight or branched alkyl group or a C1÷C4 straight or branched alkoxy group, and R2 is hydrogen, a C1÷C4 straight or branched alkyl group or a C1÷C4 straight or branched alkoxy group are also disclosed. Preferred among the compounds of formula (III) and (IV) wherein-R is a group A are those wherein R1 and R2 are C1÷C4 straight or branched alkyl groups; more preferred are those wherein both R1 and R2 are C1÷C4 straight alkyl groups; and even more preferred are those wherein both R1 and R2 are methyl.
  • Another group of preferred compounds (III) and (IV) wherein -R represents a group A are those wherein R1 is hydrogen and R2 is a C1÷C4 straight alkoxy group.
  • Example 1 Preparation of 5-amino-N,N'-bis(2,2-dimethyl-1,3-dioxan-5-yl)-2.4,6-triiodo-1,3-benzenedicarboxamide ((III): -R = a group A wherein R 1 ∼and R 2 = methyl).
  • 2,2-Dimethoxypropane (9.5 mL, 77.8 mmol) and 98% sulfuric acid (0.25 g, 2.6 mmol) are dripped into a 0.5 L vessel containing a solution of the compound of formula (II) (18.3 g, 25.9 mmol) (prepared as described in GB1472050 ) in dimethylacetamide (90 mL) stirred at room temperature. After 20 hours under stirring the solution is neutralised with NaHCO3 and concentrated under vacuum. Acetone (250 mL) and 3 % aq. NaHCO3 (50 mL) are then added to the obtained oily residue and the solid is recovered by filtration and crystallized from 70% ethanol to give the compound of the title (13 g, 16.5 mmol after drying).
    Yield: 64 %
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 2 Preparation of 5-amino-N.N'-bis(2-ethoxy-1,3-dioxan-5-yl)-2,4,6-triiodo-1,3-benzenedicarboxamide ((III): -R = a group A wherein R 1 is hydrogen and R 2 is ethox)
  • Methanesulfonic acid (0.27 g, 2.8 mmol) and triethyl orthoformate (9.25 g, 62.4 mmol) are dripped in 1 hour into a solution of the compound of formula (II) (20 g, 28.4 mmol) (prepared as described in GB1472050 ) in N,N-dimethylacetamide (150 mL) stirred at 25 °C. After 1 hour the solution is neutralised with NaHCO3 The solvent is evaporated under vacuum and the oily residue is taken up with aq. 5 % NaHC03 (300 mL).
  • The solid thus obtained is filtered and crystallized twice from 70% ethanol to afford the compound of the title (14.7 g, 18.7 mmol).
    Yield: 66 %
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 2 bis Alternative preparation of of 5-amino-N,N'-bis(2-ethoxy-1,3-dioxan-5-yD-2,4,6-triiodo-1,3-benzenedicarboxamide ((III): -R = a group A wherein R 1 is hydrogen and R 2 is ethoxy)
  • Triethyl orthoformate (18.6 g, 125.5 mmol) is added over 3 min to a solution of the compound of formula (II) (40 g, 57 mmol) and methanesulfonic acid (0.55 g, 5.7 mmol) in N,N-dimethylacetamide (400 mL), stirred at room temperature. After 15 min, the reaction mixture is neutralized with 1M NaOH (5.7 mL, 5.7 mmol) and N,N-dimethylacetamide is distilled to give an oily residue. The latter is poured into 1% aq. NaHC03 causing the formation of a white precipitate that, after 15 h under stirring, is recovered by filtration, washed with H2O and dried. The solid is then suspended in absolute ethanol (600 mL), refluxed for 3 hours and allowed to cool to room temperature. The solid is recovered by filtration, washed with EtOH (30 mL) and dried to afford the compound of the title (40 g, 48. 95 mmol) as a white solid.
    Yield: 86 %.
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 3 (comparative) Preparation of N,N'-bis[2-acetyloxy-1-[acetyloxy)methyl]-5-amino-2,4,6-triiodo-1,3-benzenedicarboxamide ((III): -R is a group B where R 3 is methyl).
  • Acetic anhydride (9 mL, 95 mmol) is dripped into a suspension of the compound of formula (II) (7 g, 10 mmol) (prepared as described in GB1472050 ) in pyridine (40 mL) stirred at 25 °C. After 3 hours, the solution obtained is added dropwise to deionized water (0.3 L) and the precipitate is recovered by filtration, washed with 5 % acetic acid, then with deionized water, and finally dried under vacuum at the temperature of 40 °C for 12 hour to obtain the compound of the title (7.86 g, 9 mmol).
    Yield: 90 %
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 3 bis (comparative) Alternative preparation of N.N'-bis[2-acetyloxy-1-[(acetyloxy)methyl]ethyl]-5-amino-2,4,6-triiodo-1,3-benzenedicarboxamide ((III): -R is a group B where R 3 is methyl)
  • The compound of formula (II) (1486 g, 2.1 mol) is loaded into a 10 L reactor containing N,N-dimethylacetamide (1.7 L) and 4-dimethylaminopyridine (12.9 g) is then added thereto. Acetic anhydride (0.9 kg, 8.82 mol) is dripped therein over about 1 hour keeping the temperature below 30 °C. The reaction mixture is stirred at room temperature for 20 hours, and then diluted with 96% ethanol (7.5 L). The precipitate is filtered, washed with 96% ethanol (2 x 1L) and dried to give the compound of the title (1715 g, 1.96 mol).
    Yield: 94 %
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 4 (comparative) Preparation of (S)-N,N'-bis[2-acetyloxy-1-[(acetyloxy)methyl]ethyl]-5-[(2-acetyloxy-1-oxopropyll)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide (IV)-R is a group B wherein R 3 is methyl)
  • The compound prepared in Example 3 (11 g, 12,6 mmol) is dissolved in N,N-dimetylacetamide (200 mL) containing gaseous HCl (0.055 g, 1.5 mmol) and the solution is maintained at a temperature comprised between 15 and 17°C. (S)-2-(Acetyloxy)propanoyl chloride (4.75 g, 31.5 mmol) is dripped therein over 30 min. and the obtained reaction mixture is stirred at 23 °C for 20 hours. The solvent is then evaporated under vacuum and the oily residue is taken up with 4 % aq. NaHCO3 (250 mL). The obtained precipitate is recovered by filtration, washed and dried to yield the compound of the title (9.9 g, 10 mmol).
    Yield: 80%
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 5 Preparation of (S)-N,N'-bis(2,2-dimethyl-1,3-dioxan-5-yl)-5-[(2-acetyloxy-1-oxopropyl)amino]-2.4,6-triiodo-1,3-benzenedicarboxamide ((IV): -R = a group A wherein R 1 and R 2 are methyll
  • The compound prepared in Example 1 (15 g, 19 mmol) is dissolved in N,N-dimethylacetamide (80 mL) containing HCl gas (0.073 g, 2 mmol). (S)-2 (Acetyloxy)propanoyl chloride (8 g, 53 mmol) is dripped over 30 min into the obtained solution cooled to 15 °C. After two hours at the same temperature, the reaction mixture is allowed to warm up to room temperature and stirred for additional 12 hours. The solvent is then evaporated under vacuum and the residue is taken up with 4 % NaHCO3 (130 mL). The solid obtained is filtered, washed and dried to give the compound of the title (14 g, 15,6 mmol).
    Yield: 82 %
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 6 Preparation of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2.4.6-triiodo-1,3-benzenedicarboxamide (I)
  • (S)-N,N'-Bis[2-acetyloxy-1-[(acetyloxy)methyl]ethyl]-5-[(2-acetyloxyl-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide (4.9 g, 5 mmol) prepared in Example 4 is admixed with deionized water (30 mL) and methanol (30 mL). The suspension is warmed to 50 °C, then 2M NaOH (12.8 mL) is dripped therein over a period of 4 hours, keeping the pH of the mixture in the range of from 10 to 11. The solution is purified on ion exchange resins columns and the neutral eluate thus obtained is concentrated under vacuum and the residue is crystallized from ethanol to give the compound of the title (2.8 g, 3.6 mmol)
    Yield: 72%. α 436 20 = 5.15 40 % H 2 O .
    Figure imgb0011
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 7 Alternative preparation of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2.4.6-triiodo-1,3-benzenedicarboxamide (I)
  • 0.2 M HCl (15 mL) is added to a solution of (S)-N,N' -bis(2,2-dimethyl-1,3-dioxan-5-yl)-5-[(2-acetyloxy-1-oxopropyl)amino]--2,4,6-triiodo-1,3-benzenedicarboxamide (9 g, 10 mmol) prepared as described in the Example 5, in methanol (60 mL), and the obtained mixture is stirred at 50 °C for 2 hours, and then cooled to 40 °C. 1M NaOH (14 mL) is then dripped therein over a period of 2 hours to keep the pH between 10.5 and 11.
  • After two hours, the reaction mixture is cooled to room temperature and purified on ionic exchange resins. The neutral eluate thus obtained, is concentrated and the residue obtained is crystallized from ethanol (80 mL). The solid is filtered and dried to give the compound of the title (I) (7 g, 9 mmol).
    Yield: 90 %
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 8 Alternative preparation of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide (I)
  • 5-Amino-N,N'-bis(2,2-dimethyl-1,3-dioxan-5-yl)-2,4,6-triiodo-1,3-benzenedicarboxamide prepared as in Example 1, is reacted as described in Example 5. The (S)-N, N'-bis(2,2-dimethyl-1,3-dioxan-5-yl)-5-[(2-acetyloxy-1-oxopropyl)amino]--2,4,6-triiodo-1,3-benzenedicarboxamide obtained from the reaction is not isolated, but directly deprotected according to the method described in Example 7 above to give the compound of the title.
    Yield: 74 %.
    The 1H-NMR, 13C-NMR, IR and MS are consistent with the indicated structure.
  • Example 9 Alternative preparation of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide (I)
  • (S)-2-(Acetyloxy)propanoyl chloride (16.5 g, 110 mmol) is added, over a period of 20 min, to a stirred solution of N,N'-bis[2-acetyloxy-1-[(acetyloxy)methyl]ethyl]-5-amino-2,4,6-triiodo-1,3-benzenedicarboxamide (53.3 g, 61.1 mmol) in N,N-dimethylacetamide (75 mL) while keeping the temperature of the reaction mixture below 30 °C. An additional amount of (S)-2-(acetyloxy)propanoyl chloride (0.9 g, 6.0 mmol) is added after 24 and 30 hours and the reaction mixture is stirred at the same temperature for further 15 hours. The reaction mixture is then concentrated to half volume and diluted with a 1:1 mixture of water/methanol (360 mL). The resulting suspension is heated to 45 °C and 2M NaOH (225 mL, 450 mmol) is added over 30 min. After 2 h the hydrolysis is complete, the solution is concentrated to half volume, extracted with CH2Cl2 (6 x 100 mL) and loaded onto two ion exchange resin columns (Dowex® C350, H+ form, 200 mL; Relite® MG1, OH-form, 160 mL) that are eluted with water. The eluate is evaporated and the solid residue (49 g) thus obtained is crystallized from ethanol (450 mL). The recovered solid (40.5 g) is dissolved in H20 (400 mL) and the solution loaded onto an Amberlite® (8) XAD-16. 00 resin column (160 mL) that is eluted with water. The eluate is evaporated and the residue dried to afford lopamidol (40.0 g, 51. 5 mmol) as a white solid.
    Yield: 84 % α 436 20 = 5.15 40 % H 2 O .
    Figure imgb0012
  • Example 10 Alternative preparation of (S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide (I)
  • (S)-2-(Acetyloxy) propanoyl chloride (16.5 g, 110 mmol) is added, over 20 min to a stirred solution of N,N'-bis[2-acetyloxy-1-[(acetyloxy)methyl]ethyl]-5-amino-2,4,6-triiodo-1,3-benzenedicarboxamide (53.3 g, 61.1 mmol) in N,N-dimethylacetamide (75 mL) while keeping the temperature of the reaction mixture below 30 °C. A further amount of (S)-2-(acetyloxy) propanoyl chloride (0.9 g, 6.0 mmol) is added after 24 and 30 hours and the reaction mixture is stirred at the same temperature for additional 15 hours. 5M NaOH (90 mL, 450 mmol) is dripped over a period of 2 hours into the reaction mixture vigorously stirred at 45 °C. After two hours the mixture is concentrated under vacuum and reintegrated with additional N,N-dimethylacetamide (200 mL). After two hours at room temperature the resulting suspension is filtered and the solid washed with N,N-dimethylacetamide (2 X 20 mL). The mother liquors, combined with the washings, are concentrated to an oily residue, which is diluted with water (200 mL) and nanofiltered. The retentate is loaded onto an Amberlite® XAD-16.00 resin column (160 mL) that is eluted with water. The eluate is concentrated and loaded onto two ion exchange resin columns (Dowex® C350 15 mL, Relite® MG1 10 mL). The eluate is concentrated and the solid residue is crystallized from ethanol to afford Iopamidol (41.2 g, 53 mmol).
    Yield: 87%. α 436 20 = 5.15 40 % H 2 O .
    Figure imgb0013

Claims (5)

  1. Process for the preparation of (S)-N,N'-bis[2-hydroxy-1 (hydroxymethyl) ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide of formula (I)
    Figure imgb0014
    starting from the compound of formula (II)
    Figure imgb0015
    which process comprises
    a) reacting the compound of formula (II) with a suitable protecting agent, to give a compound of formula (III)
    Figure imgb0016
    wherein R is a group of formula A and
    Figure imgb0017
    wherein R1 is a hydrogen atom, a C1-C4 straight or branched alkyl group or a C1-C4 straight or branched alkoxy group and R2 is hydrogen, a C1-C4 straight or branched alkyl group or a C1-C4 straight or branched alkoxy group;
    b) acylating the amino group in position 5 of the intermediate compound of formula (III), by reaction with a (S)-2-(acetyloxy)propanoyl chloride to give a compound of formula (IV)
    Figure imgb0018
    wherein R is defined above; and
    c) removing all the acyl groups present in the compound of formula (IV) under basic conditions, with prior cleavage of the cyclic protection under acidic conditions,
    wherein intermediate compound (IV) obtained in step b) is further reacted without being isolated.
  2. The process of claim 1 wherein R1 and R2 are C1-C4 straight alkyl groups.
  3. The process of claim 1 wherein step a) is carried out by reacting the compound of formula (II) with at least 2 mol per mol of compound (II) of a compound selected from di-(C1-C4)alkoxy-methane, aldehydes and ketones of formula R1COR2 (possibly in the corresponding acetal or ketal related forms) wherein R1 is a hydrogen atom or a C1÷C4 straight or branched alkyl group and R2 is a C1-C4 straight or branched alkyl group and orthoesters R1C (R2)3 when at least R2 is an alkoxy group, in the presence of from about 0.1 to about 2 mol of an acid per mol of compound of formula (II).
  4. The process of claim 1 wherein the acylation of step b) is carried out by reacting the compounds (III) with at least one mol of (S)-2-(acetyloxy)-propanoyl chloride in an inert dipolar aprotic solvent and in presence of from about 0.1 to about 0.4 mol per mol of product of formula (III) of an acid.
  5. The process of claim 1 wherein removal of the acyl group of the compound of formula (IV) under basic conditions according to step c) is carried out in water or in a mixture of water and an organic solvent miscible therewith, keeping the pH of the reaction mixture between 10 and 11 by the addition of a strong inorganic base, and is preceded by cleavage of the cyclic protections of the carboxamido hydroxy groups under acidic conditions.
EP15179960.8A 2000-12-01 2001-11-29 Process for the preparation of iopamidol Expired - Lifetime EP2975021B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000MI002601A IT1319671B1 (en) 2000-12-01 2000-12-01 PROCESS FOR THE PREPARATION OF (S) -N, N'-BIS (2-IDROSSI-1- (IDROSSIMETIL) ETIL) -5 - ((2-IDROSSI-1-OSSOPROPIL) AMINO)
EP01998532.4A EP1353899B1 (en) 2000-12-01 2001-11-29 A process for the preparation of iopamidol

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
EP01998532.4A Division-Into EP1353899B1 (en) 2000-12-01 2001-11-29 A process for the preparation of iopamidol
EP01998532.4A Division EP1353899B1 (en) 2000-12-01 2001-11-29 A process for the preparation of iopamidol

Publications (2)

Publication Number Publication Date
EP2975021A1 EP2975021A1 (en) 2016-01-20
EP2975021B1 true EP2975021B1 (en) 2017-07-26

Family

ID=11446159

Family Applications (2)

Application Number Title Priority Date Filing Date
EP15179960.8A Expired - Lifetime EP2975021B1 (en) 2000-12-01 2001-11-29 Process for the preparation of iopamidol
EP01998532.4A Expired - Lifetime EP1353899B1 (en) 2000-12-01 2001-11-29 A process for the preparation of iopamidol

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01998532.4A Expired - Lifetime EP1353899B1 (en) 2000-12-01 2001-11-29 A process for the preparation of iopamidol

Country Status (22)

Country Link
US (2) US7034183B2 (en)
EP (2) EP2975021B1 (en)
JP (1) JP4263910B2 (en)
KR (1) KR100855765B1 (en)
CN (1) CN100345821C (en)
AU (1) AU2002217068B8 (en)
BG (1) BG66276B1 (en)
BR (1) BRPI0115785B8 (en)
CA (1) CA2430339C (en)
CZ (1) CZ304015B6 (en)
EA (1) EA005922B1 (en)
HU (1) HU230702B1 (en)
IL (2) IL156188A0 (en)
IT (1) IT1319671B1 (en)
MX (1) MXPA03004774A (en)
NO (1) NO328627B1 (en)
NZ (1) NZ526188A (en)
PL (1) PL204819B1 (en)
SK (1) SK287570B6 (en)
UA (1) UA75956C2 (en)
WO (1) WO2002044132A1 (en)
ZA (1) ZA200304199B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8624061B2 (en) 2008-11-18 2014-01-07 Bracco Imaging S.P.A. Process for the preparation of iodinated contrast agent
EP2230227A1 (en) 2009-03-20 2010-09-22 Bracco Imaging S.p.A Process for the preparation of triiodinated carboxylic aromatic derivatives
US20110021833A1 (en) * 2009-07-21 2011-01-27 Ge Healthcare As Crystallization of an intermediate for synthesizing non-ionic x-ray contrast agents
US20110021822A1 (en) * 2009-07-21 2011-01-27 Ge Healthcare As continuous deacetylation and purification process in synthesis of non-ionic x-ray contrast agents
PT105770B (en) * 2011-06-24 2013-07-08 Hovione Farmaciencia S A NEW INTERMEDIARY AND ITS USE IN THE PREPARATION OF CONTRACT TRIUMPHENT AGENT
CN103382160B (en) * 2012-05-02 2017-10-27 上海海神化学生物科技有限公司 The synthesis of Iopamidol and its preparation of synthetic intermediate
LT3066071T (en) * 2013-11-05 2018-09-10 Bracco Imaging S.P.A. Process for the preparation of iopamidol
CN104098484A (en) * 2014-07-21 2014-10-15 杭州杜易科技有限公司 Iopamidol preparation method
CN106366016B (en) * 2015-07-22 2019-03-05 连云港润众制药有限公司 A kind of Preparation Method And Their Intermediate of Iopromide
CN106366015B (en) * 2015-07-22 2019-01-25 正大天晴药业集团股份有限公司 A kind of Preparation Method And Their Intermediate of Iopromide
WO2018104228A1 (en) * 2016-12-05 2018-06-14 Bracco Imaging Spa Mechanochemical synthesis of radiographic agents intermediates
GB202009917D0 (en) 2020-06-29 2020-08-12 Ge Healthcare As Process for the preparation of iopamidol
CN115010617B (en) * 2022-07-11 2024-06-11 安徽普利药业有限公司 Preparation method of iopamidol

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH608189A5 (en) 1974-12-13 1978-12-29 Savac Ag
CH616403A5 (en) 1975-10-29 1980-03-31 Bracco Ind Chimica Spa Process for the preparation of 2,4,6-triodoisophthalamides which are readily soluble in water.
CH627653A5 (en) 1977-03-28 1982-01-29 Bracco Ind Chimica Spa Non-ionic X-ray contrast media and process for the preparation of their radiopaque components
IT1193211B (en) * 1979-08-09 1988-06-15 Bracco Ind Chimica Spa 2,4,6-TRIIODE-ISOPHTHALIC ACID DERIVATIVES, METHOD FOR THEIR PREPARATION AND CONTRAST MEANS THAT CONTAIN THEM
IT1207226B (en) * 1979-08-09 1989-05-17 Bracco Ind Chimica Spa 2,4,6-TRIIODE-ISOPHTHALIC ACID DERIVATIVES, METHOD FOR THEIR PREPARATION AND CONTRAST MEANS THAT CONTAIN THEM.
US4396598A (en) * 1982-01-11 1983-08-02 Mallinckrodt, Inc. Triiodoisophthalamide X-ray contrast agent
US5278311A (en) 1992-06-05 1994-01-11 E. R. Squibb & Sons, Inc. Nonionic radiographic contrast agents
IL110391A (en) 1993-07-30 1998-12-06 Zambon Spa Process for the crystallization of iopamidol
US5811581A (en) 1994-08-04 1998-09-22 Dibra S.P.A. Process for the purification of opacifying contrast agents
IT1282653B1 (en) 1996-02-20 1998-03-31 Bracco Spa DEVICE AND METHOD FOR THE REGENERATION OF MIXED BEDS OF ION EXCHANGE RESINS
US6803485B2 (en) 1999-02-26 2004-10-12 Bracco Imaging S.P.A. Process for the preparation of iopamidol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
EP1353899B1 (en) 2016-01-20
BG66276B1 (en) 2012-12-28
JP4263910B2 (en) 2009-05-13
US7368101B2 (en) 2008-05-06
NZ526188A (en) 2004-11-26
CN1478068A (en) 2004-02-25
IL156188A0 (en) 2003-12-23
NO328627B1 (en) 2010-04-12
AU1706802A (en) 2002-06-11
EA200300513A1 (en) 2003-12-25
AU2002217068B2 (en) 2006-11-02
AU2002217068B8 (en) 2007-02-01
MXPA03004774A (en) 2004-03-26
KR20030077546A (en) 2003-10-01
US7034183B2 (en) 2006-04-25
EP1353899A1 (en) 2003-10-22
BR0115785B1 (en) 2014-11-04
US20060106253A1 (en) 2006-05-18
UA75956C2 (en) 2006-06-15
BR0115785A (en) 2003-10-21
PL204819B1 (en) 2010-02-26
ITMI20002601A1 (en) 2002-06-01
HUP0302758A3 (en) 2005-04-28
NO20032440D0 (en) 2003-05-28
HU230702B1 (en) 2017-10-30
ZA200304199B (en) 2004-06-24
KR100855765B1 (en) 2008-09-01
BG107824A (en) 2004-02-27
CN100345821C (en) 2007-10-31
IL156188A (en) 2008-12-29
HUP0302758A2 (en) 2003-12-29
IT1319671B1 (en) 2003-10-23
CA2430339A1 (en) 2002-06-06
PL363799A1 (en) 2004-11-29
SK6562003A3 (en) 2003-10-07
WO2002044132A1 (en) 2002-06-06
SK287570B6 (en) 2011-03-04
EP2975021A1 (en) 2016-01-20
NO20032440L (en) 2003-05-28
US20040082812A1 (en) 2004-04-29
EA005922B1 (en) 2005-08-25
JP2004514705A (en) 2004-05-20
CA2430339C (en) 2011-01-25
CZ304015B6 (en) 2013-08-21
BRPI0115785B8 (en) 2021-05-25
CZ20031506A3 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
US7368101B2 (en) Process for the preparation of iopamidol and the new intermediates therein
JP4674297B2 (en) Method for producing D-erythro-2,2-difluoro-2-deoxy-1-oxoribose derivative
EP3166928B1 (en) Process for the preparation of 3-hydroxypicolinic acids
US4851588A (en) Novel process for the preparation of bronopol
AU2002217068A1 (en) A process for the preparation of iopamidol and the new intermediates therein
WO2004087640A1 (en) Process for the manufacture of n-alkoxalyl-alaninates
KR100936306B1 (en) Process for the preparation of 3-[2-3,4-dimethoxy-benzoyl-4,5-dimethoxy-phenyl]-pentan-2-one
SK9997A3 (en) Process for the stereoselective preparation of heterobicyclic alcohol enantiomer
US5861533A (en) Process for nitrosation of C-H-acidic compounds
JP3259191B2 (en) Synthesis of 2,2'-anhydroarabinosyl thymine derivatives
JP4336913B2 (en) Method for producing amide derivative
US6365755B1 (en) Ammonium 3,5,6-trihydroxyhexanoate derivatives and preparation process thereof
JP2805114B2 (en) α, β-unsaturated ketoester derivatives
KR20240050303A (en) Method for producing 2’ modified guanosine compounds
EP1451178A1 (en) Processes for preparing beta-d-ribofuranose derivatives
JPH0812641A (en) Syn-2,4-pentanediol derivative and its production

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1353899

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: RO

17P Request for examination filed

Effective date: 20160719

RAX Requested extension states of the european patent have changed

Extension state: RO

Payment date: 20160719

RBV Designated contracting states (corrected)

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170224

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRACCO IMAGING SPA

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1353899

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: RO

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 912231

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 60150537

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20170726

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 912231

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171027

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 60150537

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

26N No opposition filed

Effective date: 20180430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171129

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20171130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170726

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20201127

Year of fee payment: 20

Ref country code: CH

Payment date: 20201202

Year of fee payment: 20

Ref country code: IT

Payment date: 20201123

Year of fee payment: 20

Ref country code: FR

Payment date: 20201125

Year of fee payment: 20

Ref country code: GB

Payment date: 20201127

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60150537

Country of ref document: DE

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20211128

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20211128